Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)
- 1 October 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 13 (S4), 10-15
- https://doi.org/10.1634/theoncologist.13-s4-10
Abstract
Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) blockade therapies have been evaluated in clinical trials and have shown promise as possible options for treating patients with cancer. One agent under investigation is tremelimumab (CP-675,206), a monoclonal antibody that has been demonstrated to be a safe and efficacious treatment in patients with malignant melanoma. Results of a phase I clinical trial suggested that a dose of 15 mg/kg of tremelimumab would be the maximum-tolerated dose, with the most common grade 3–4 toxicities being diarrhea and rash. Pharmacokinetic studies showed that the postinfusion plasma concentration and area under the plasma disposition curve both increased in an approximately proportional manner with dose. Studies also showed that tremelimumab has a low clearance (0.132 ml/h·kg), a small volume of distribution (81.2 ml/kg), and a long terminal-phase half-life (22.1 days). A pivotal phase II clinical trial assessing single-agent tremelimumab as second-line therapy in metastatic melanoma has completed accrual, with response rate as the primary endpoint. A pivotal phase III trial has also completed accrual; that study compared the overall survival of previously untreated patients receiving single-agent tremelimumab versus dacarbazine or temozolomide.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 8 references indexed in Scilit:
- Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with CancerThe Oncologist, 2007
- Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanomaJournal of Clinical Oncology, 2007
- Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II studyJournal of Clinical Oncology, 2007
- Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumabJournal of Clinical Oncology, 2006
- Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanomaCancer, 2006
- Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206Journal of Clinical Oncology, 2005
- Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanomaJournal of Clinical Oncology, 2005
- Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism in the Cytotoxic T-Lymphocyte Antigen-4 GeneChest, 2002